CTLA4 and cancer: A relevant mechanism that account for the progressive loss of immune function in cancer is the sustained signaling of multiple inhibitory receptors, commonly known as checkpoints, such as PD1 and CTLA-4, which down-regulate the antitumor immune response (14, 39).